Key Highlights

• The company's financial results for the year to 30 June 2026 reflect a full year of sales.

• Net Ryoncil product sales were US$115.2 million, after a 13.4 per cent gross-to-net adjustment, compared with US$11.3 million in the prior year.

• Total Revenue for the year was US$120.3 million, up from US$17.2 million, including US$5.1 million of Royalty revenue.

• The net loss narrowed to US$57.5 million from US$102.1 million, a fall of 44 per cent.

What do Mesoblast (ASX:MSB)'s latest results actually show about its first commercial product? In short, they show a biotech that has moved from almost no product sales to a revenue-generating Business in about a year, while still carrying the regulatory and clinical uncertainty typical of the sector.

The central development: Ryoncil becomes a commercial product

Mesoblast (ASX:MSB) sells Ryoncil (remestemcel-L), a cell therapy approved by the US Food and Drug Administration (FDA) for paediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD) in patients aged two months and older. The company's financial results for the year to 30 June 2026 reflect a full year of sales.

Net Ryoncil product sales were US$115.2 million, after a 13.4 per cent gross-to-net adjustment, compared with US$11.3 million in the prior year. That change is the main reason the company's financial profile looks so different from twelve months earlier.

FY26 financial results

Total revenue for the year was US$120.3 million, up from US$17.2 million, including US$5.1 million of royalty revenue. Gross Profit was US$103.6 million as reported.

The net loss narrowed to US$57.5 million from US$102.1 million, a fall of 44 per cent. The loss in the second half was US$17.3 million. Operating cash outflow was US$43.8 million, against US$50.0 million a year earlier.

Cash at 30 June 2026 was US$102.9 million, down from US$161.6 million. It did not give numerical financial guidance in the release.

The September 2026 quarter

In its quarterly update on 16 October 2026, Mesoblast reported net Ryoncil revenue of about US$28 million, compared with about US$19 million a year earlier. Reports indicate that was lower than the roughly US$36 million recorded in the June 2026 quarter, a sequential decline of about 22 per cent.

The company attributed part of the softness to a seasonal slowdown in July and August, saying new patient starts reached a record level in September. That is management's description; the underlying patient numbers were not disclosed in the coverage reviewed.

Net operating cash spend was about US$2.3 million, versus US$14.9 million a year earlier, and cash at 30 September was about US$99 million. Ryoncil is now available through 54 onboarded US treatment centres.

What Mesoblast does and where revenue comes from

Mesoblast develops allogeneic, or donor-derived, cell therapies for inflammatory and degenerative conditions. Today almost all revenue comes from Ryoncil, which is sold in the United States to transplant centres. A smaller amount arrives as royalties.

That concentration is the key feature of the business. One product, one approved indication and one main market mean results can swing with patient numbers, ordering patterns and reimbursement, as the quarter-on-quarter movement illustrates.

Pipeline and regulatory status

Several programmes aim to widen the commercial base, but none has regulatory approval beyond the paediatric Ryoncil indication.

For adults with SR-aGvHD, a registration trial of Ryoncil combined with ruxolitinib as a second-line therapy has begun enrolling, with up to 40 US sites expected to be activated this year. Mesoblast has reported 76 per cent Day 100 survival in adults and adolescents treated in the third-line setting, against a historical 20 to 30 per cent. That comparison is to historical data, not a controlled trial, and it does not establish efficacy or approval in adults.

The FDA has cleared an investigational new drug application for a registrational trial in Duchenne muscular dystrophy in children aged five to nine. Clearance allows a trial to proceed; it says nothing about whether the treatment works.

For rexlemestrocel-L, Mesoblast has received a Biologics licence application filing number and asked for a modular review in preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients with a left ventricular assist device. The request is due to be discussed with the FDA, and no acceptance or approval has been announced. A Phase 3 trial in chronic low back pain has completed treatment of 350 patients, with top-line results expected around mid-2027.

In September 2026 the FDA also approved an additional potency assay for releasing and monitoring commercial Ryoncil batches, a Manufacturing quality step rather than a clinical milestone.

Sector conditions and competition

Cell therapy is capital-intensive and tightly regulated. Manufacturing consistency, Supply and payer coverage are as important as clinical data. In GvHD, Ryoncil sits alongside established drugs such as ruxolitinib, which the adult trial uses in combination, so its place in treatment depends on physician uptake and evidence.

Pricing and reimbursement add another layer. Ryoncil's sales depend on hospitals and payers accepting its cost, and the 13.4 per cent gross-to-net adjustment in FY26 shows that discounts and rebates already reduce reported revenue. Changes to that adjustment would flow straight into net sales, so investors typically watch it closely alongside patient numbers.

Risks and upcoming developments

The main risks are reliance on a single product, variability in quarterly sales, the pace at which cash is consumed, and the binary nature of regulatory and trial outcomes. The cash balance of about US$99 million and the new Credit Facility provide some funding runway, though future needs depend on sales and trial spending.

Developments to watch include FDA feedback on the modular review request, activation of US sites for the adult trial, the next quarterly update, and the chronic low back pain Phase 3 read-out. Any of these could be positive or negative, and timelines can change.

The takeaway

The numbers show real commercial progress and a narrower loss, tempered by concentration and development risk. Clinical and regulatory claims should be judged against what has actually been approved: only paediatric SR-aGvHD at this stage.